Antoinette Paone

Satellos Bioscience Inc., a clinical-stage biotechnology company focused on developing life-improving medicines for degenerative muscle diseases, has appointed Antoinette Paone as Chief Development Officer (CDO) and Head of Regulatory Affairs. 

Ms. Paone brings extensive expertise in regulatory strategy across the full product lifecycle, from clinical development through regulatory approval, including leadership roles on the cystic fibrosis therapies Kalydeco and Orkambi at Vertex Pharmaceuticals (Nasdaq: VRTX).

Ms. Paone joins Satellos from Generation Bio (Nasdaq: GBIO), where she most recently served as Chief Operating Officer. During her tenure, she played a pivotal role in scaling the company from a start-up to a development-ready organization, building and leading critical functions such as regulatory strategy, quality, chemistry, manufacturing and controls (CMC), technical operations, and program management. She also served on the executive team that led multiple equity financings over four years, including a successful initial public offering and the establishment of a strategic partnership with Moderna.

Prior to Generation Bio, Ms. Paone spent more than a decade at Vertex Pharmaceuticals, most recently as Vice President and Head of North American Regulatory Affairs Strategy. In this role, she led regulatory efforts for multiple novel small-molecule therapies for cystic fibrosis, including Kalydeco and Orkambi. Earlier in her career, she held positions at Merck & Co. and Millennium Pharmaceuticals, Inc.

Ms. Paone holds an MBA from Bentley College, a Master of Science in Organic Chemistry from Yale University, and a Bachelor of Science in Chemistry from Fordham University. Her appointment further strengthens Satellos’ leadership team as the company advances its clinical programs and works to deliver meaningful therapies to patients with degenerative muscle diseases.